Fairchild Air Force Base pharmacy taps ‘Innovation’ for automation
Fairchild Air Force Base pharmacy in Washington State has implemented Innovation’s PharmASSIST Light-Way storage and retrieval system with initial use as a will call management system for prescription storage and patient pickup, the maker of pharmacy automation solutions announced on Monday.
“We’re extremely pleased with how quickly and smoothly this initial installation and end-user training of PharmASSIST Light-Way went at Fairchild AFB. Feedback has been very positive with the staff touting Light-Way’s user friendliness as key to their early productivity,” stated Chris Cole, program manager, federal healthcare at Innovation. ”As with any new product we introduce, we’re actively soliciting user feedback from their team with a goal of continually improving the product in the various modalities it supports.”
The PharmASSIST Light-Way pick-to-light technology is designed to offer a simple means of placing and picking prescriptions into the system’s storage locations (i.e., cubbies/slots). All picking and placing is controlled via barcode scanning and guided with pick-to-light queuing. This reduces the opportunity for human error. All storage locations are size configurable and light up when users place prescriptions into the locations or when a patient presents at the pick-up window. To drive greater efficiencies, the system is integrated with the pharmacy’s PharmASSIST Symphony workflow management platform, which is used throughout U.S. Air Force Pharmacy.
According to Innovation, it foresees expanded use of PharmASSIST Light-Way as a productivity tool at other steps in the prescription fulfillment process. For example, the system has the capability to be used to collate prescriptions between filling and verification, and also for inventory management for picking fast moving inventory at manual filling stations to speed up the manual filling process.
Perrigo confirms first-to-file patent challenge for generic plaque psoriasis treatment
DUBLIN — Perrigo announced on Monday that Sun Pharmaceutical Industries and MiCal Pharmaceuticals has initiated patent litigations in the U.S. District Court for the District of Delaware and in the U.S. District Court for the Western District of Michigan regarding Perrigo’s Paragraph IV Abbreviated New Drug Application for halobetasol propionate lotion, 0.05% (a generic version of Ultravate Lotion), asserting a patent listed in the Orange Book for Ultravate Lotion.
This action formally initiates the litigation process under the Hatch-Waxman Act.
Ultravate Lotion, 0.05% is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.
“This first-to-file Paragraph IV ANDA is another example of making long-term investments in our extended topicals strategy. The Rx team continues to invest in bringing important products to market that provide savings to patients and the healthcare system,” stated Perrigo executive vice president and president Rx Pharmaceuticals John Wesolowski.
Annual market sales for the 12 months ended March 2018 were $17 million as measured by IQVIA.
PantheRx to distribute Jynarque for patients battling ADPKD
PITTSBURGH — Otsuka America Pharmaceutical has selected PantheRx Specialty Pharmacy, a Pennsylvania-based pharmacy with a focus on rare diseases, to distribute Jynarque (tolvaptan), the only FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD). According to PantheRx, it is one of just three pharmacies providing nationwide access to the medication.
ADPKD is one of the most common, life-threatening genetic diseases, diagnosed in 140,000 Americans. In patients with this condition, fluid-filled cysts develop, enlarge in both kidneys, and eventually lead to kidney failure. ADPKD is the fourth leading cause of kidney failure and more than 50 percent of people with this condition will develop kidney failure by age 57.
“We are delighted to offer Jynarque as a breakthrough treatment to patients impacted by ADPKD, a rare and devastating condition” stated Gordon Vanscoy, chairman and CEO at PantheRx. “With our award-winning focus on patient satisfaction, PantheRx’s RareCare teams work diligently to ensure our patients receive innovative therapy solutions while providing the highest-touch care possible.”
Jynarque is a selective vasopressin V2-receptor antagonist. This means it blocks vasopressin, an anti-diuretic hormone secreted by the pituitary gland, which plays a key role in the fluid balance of the kidneys. By blocking this hormone, the drug can decrease cyst-cell proliferation and fluid secretion, which ultimately can reduce cyst growth. Jynarque was shown to reduce the rate of kidney function decline by 35 percent over a 12-month period when compared with a placebo, in patients with ADPKD.